Dr. Douglas R. Johnson, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 231 Weaver St, Unit F, Fall River, MA 02720 Phone: 508-679-1400 Fax: 508-679-1449 |
Madhavi S.v. Prasad, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 851 Middle St Ste 3300, Fall River, MA 02721 Phone: 774-613-1444 |
Dr. John A. Magnotta, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 363 Highland Ave, Fall River, MA 02720 Phone: 508-973-7643 Fax: 508-973-7650 |
Dr. Parakrama M. Ananta, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 231 Weaver St, Unit F, Fall River, MA 02720 Phone: 508-679-1400 Fax: 508-679-1449 |
Dr. Ajit C. Mirani, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 231 Weaver St, Unit F, Fall River, MA 02720 Phone: 508-679-1400 Fax: 508-679-1449 |
Dr. Andrew Mazur, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 231 Weaver St, Unit F, Fall River, MA 02720 Phone: 508-679-1400 Fax: 508-679-1449 |
News Archive
A Johns Hopkins undergraduate has constructed a new type of microchip that can move and isolate DNA and protein molecules. He believes that by linking the chip with analysis equipment, a user could identify medical ailments, monitor a patient's health or detect viruses and other biohazards before they spread.
A new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine takes a comprehensive look at evidence on the human health effects of e-cigarettes.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Board of Appeals of the European Patent Office (EPO) has ruled that claims of the Kreutzer-Limmer '945 (EP 1214945) patent meet needed requirements under European patent law. The '945 patent comprises broad claims covering the length and certain structural requirements for siRNAs that are important for advancement of RNAi therapeutics.
Oragenics has announced that the US Patent office has issued a fourth patent (No. 7,067,125), that further describes the composition and uses of the company's exclusively licensed novel antibiotic peptide, MU1140.
A team of researchers at the University of Trieste in Italy aimed to determine the extent and the causes of lung damage from COVID-19 to better understand the pathological correlates of the disease.
› Verified 4 days ago